Opdivo (nivolumab)

Nivolumab, marketed as Opdivo by Bristol Myers Squibb, is a PD-1 blocking antibody used in multiple oncology settings. FDA prescribing information and approval histories document its use alone and in combination with ipilimumab and other agents.

• Melanoma — advanced and adjuvant settings per FDA label.
• Non-small cell lung cancer — including neoadjuv/adjuvant pathways in FDA records.
• Renal cell carcinoma — documented combination and monotherapy approvals.
• Hepatocellular carcinoma, urothelial carcinoma, and other solid tumors per Drugs@FDA.

Opdivo competes directly with pembrolizumab and other checkpoint inhibitors. Head-to-head positioning varies by indication, line of therapy, and combination regimen—all verifiable through FDA labels and trial registrations rather than anecdotal share estimates.

• Initial FDA approvals in melanoma documented in regulatory records.
• Combination approvals with ipilimumab across multiple tumor types.
• Adjuvant and perioperative label expansions tracked in FDA databases.

• Bristol Myers Squibb